Skip to main content

Search

16 result(s) for 'author#Stian Knappskog' within BMC

Page 1 of 1

Sort by: Relevance | Date

  1. Subclonal evolution during primary breast cancer treatment is largely unexplored. We aimed to assess the dynamic changes in subclonal composition of treatment-naïve breast cancers during neoadjuvant chemotherapy.

    Authors: Andreas Venizelos, Christina Engebrethsen, Wei Deng, Jürgen Geisler, Stephanie Geisler, Gjertrud T. Iversen, Turid Aas, Hildegunn S. Aase, Manouchehr Seyedzadeh, Eli Sihn Steinskog, Ola Myklebost, Sigve Nakken, Daniel Vodak, Eivind Hovig, Leonardo A. Meza-Zepeda, Per E. Lønning…
    Citation: Genome Medicine 2022 14:86
    Content type: Research Published on:

  2. The effect of TP53 mutations on chemosensitivity in breast cancer is a controversial issue. In an elegant paper in Cancer Cell, Jackson and colleagues report wtp53 protein to block anti-tumour effects of doxorubi...

    Authors: Per E Lønning and Stian Knappskog
    Citation: Breast Cancer Research 2012 14:325
    Content type: Viewpoint Published on:

  3. While germline CHEK2 mutations have been linked to a moderately elevated cancer risk, to date, a limited number of such mutations have been identified. Recently, we reported a germline nonsense mutation (C283T; R...

    Authors: Stian Knappskog, Beryl Leirvaag, Liv B. Gansmo, Pål Romundstad, Kristian Hveem, Lars Vatten and Per E. Lønning
    Citation: Hereditary Cancer in Clinical Practice 2016 14:19
    Content type: Research Published on:

  4. The editors of BMC Medical Genetics would like to thank all our reviewers who have contributed to the journal in Volume 16 (2015).

    Authors: Timothy R. Sands
    Citation: BMC Medical Genetics 2016 17:12
    Content type: Reviewer acknowledgement Published on:

  5. Mutations affecting p53 or its upstream activator Chk2 are associated with resistance to DNA-damaging chemotherapy in breast cancer. ATM (Ataxia Telangiectasia Mutated protein) is the key activator of p53 and ...

    Authors: Stian Knappskog, Ranjan Chrisanthar, Erik Løkkevik, Gun Anker, Bjørn Østenstad, Steinar Lundgren, Terje Risberg, Ingvil Mjaaland, Beryl Leirvaag, Hrvoje Miletic and Per E Lønning
    Citation: Breast Cancer Research 2012 14:R47
    Content type: Research article Published on:

  6. The number of tumor suppressor genes for which germline mutations have been linked to cancer risk is steadily increasing. However, while recent reports have linked constitutional normal tissue promoter methyla...

    Authors: Deepak B. Poduval, Elisabet Ognedal, Zuzana Sichmanova, Eivind Valen, Gjertrud T. Iversen, Laura Minsaas, Per E. Lønning and Stian Knappskog
    Citation: Clinical Epigenetics 2020 12:131
    Content type: Research Published on:

  7. The tumor suppressor pRb plays a key role regulating cell cycle arrest, and disturbances in the RB1 gene have been reported in different cancer forms. However, the literature reports contradictory findings with r...

    Authors: Elisabet Ognedal Berge, Stian Knappskog, Stephanie Geisler, Vidar Staalesen, Marec Pacal, Anne-Lise Børresen-Dale, Pål Puntervoll, Johan Richard Lillehaug and Per Eystein Lønning
    Citation: Molecular Cancer 2010 9:173
    Content type: Research Published on:

  8. In this letter, we respond to and discuss the recent publication by Al-Moghrabi et al.: Methylation of BRCA1 and MGMT genes in white blood cells are transmitted from mothers to daughters. We discuss their finding...

    Authors: Per Eystein Lønning and Stian Knappskog
    Citation: Clinical Epigenetics 2018 10:128
    Content type: Letter to the Editor Published on:

  9. While BRCA mutation carriers possess a 20-40% lifetime risk of developing ovarian cancer, knowledge about genetic modifying factors influencing the phenotypic expression remains obscure. We explored the distribut...

    Authors: Merete Bjørnslett, Stian Knappskog, Per Eystein Lønning and Anne Dørum
    Citation: BMC Cancer 2012 12:454
    Content type: Research article Published on:

  10. The del1518 (rs3730485) polymorphism is an in/del variant in the MDM2 promoter P1. The variant is in complete linkage disequilibrium with MDM2 SNP309 (rs2279744) and has previously been found associated with an i...

    Authors: Liv B. Gansmo, Merete Bjørnslett, Mari Kyllesø Halle, Helga B. Salvesen, Pål Romundstad, Kristian Hveem, Lars Vatten, Anne Dørum, Per E. Lønning and Stian Knappskog
    Citation: BMC Cancer 2017 17:97
    Content type: Research article Published on:

  11. The murine double minute 2 (MDM2) is an oncogene and a negative regulator of the tumor suppressor protein p53. MDM2 is known to be amplified in numerous human cancers, and upregulation of MDM2 is considered to be...

    Authors: Johanna Huun, Liv B. Gansmo, Bård Mannsåker, Gjertrud Titlestad Iversen, Jan Inge Øvrebø, Per E. Lønning and Stian Knappskog
    Citation: BMC Cell Biology 2017 18:17
    Content type: Research article Published on:

  12. Uterine serous carcinoma (USC) is a rare but aggressive subtype of endometrial carcinoma. Large-scale comprehensive efforts have resulted in an improved molecular understanding of its pathogenesis, and the p53...

    Authors: Katharina Bischof, Stian Knappskog, Ingunn Stefansson, Emmet Martin McCormack, Jone Trovik, Henrica Maria Johanna Werner, Kathrine Woie, Bjorn Tore Gjertsen and Line Bjorge
    Citation: BMC Cancer 2018 18:684
    Content type: Research article Published on:

  13. Reliable methods are needed to identify patients with early-stage cancer or high-grade precancerous lesions in the pancreas. Analysis of pancreatic juice to detect somatic mutations could represent one such ap...

    Authors: Man Hung Choi, Eline Mejlænder-Andersen, Sophia Manueldas, Khadija El Jellas, Solrun J. Steine, Kjersti Tjensvoll, Hege Aase Sætran, Stian Knappskog, Dag Hoem, Oddmund Nordgård, Randi Hovland and Anders Molven
    Citation: BMC Cancer 2019 19:11
    Content type: Research article Published on:

  14. Locally advanced breast cancer is a heterogeneous disease with respect to response to neoadjuvant chemotherapy (NACT) and survival. It is currently not possible to accurately predict who will benefit from the ...

    Authors: Christine Aaserød Pedersen, Maria Dung Cao, Thomas Fleischer, Morten B. Rye, Stian Knappskog, Hans Petter Eikesdal, Per Eystein Lønning, Jörg Tost, Vessela N. Kristensen, May-Britt Tessem, Guro F. Giskeødegård and Tone F. Bathen
    Citation: Breast Cancer Research 2022 24:43
    Content type: Research Published on:

  15. Epithelial to mesenchymal transition (EMT) is a well-characterized process of cell plasticity that may involve metabolic rewiring. In cancer, EMT is associated with malignant progression, tumor heterogeneity, ...

    Authors: Gro V. Røsland, Sissel E. Dyrstad, Deusdedit Tusubira, Reham Helwa, Tuan Zea Tan, Maria L. Lotsberg, Ina K. N. Pettersen, Anna Berg, Charlotte Kindt, Fredrik Hoel, Kirstine Jacobsen, Ari J. Arason, Agnete S. T. Engelsen, Henrik J. Ditzel, Per E. Lønning, Camilla Krakstad…
    Citation: Cancer & Metabolism 2019 7:6
    Content type: Research Published on:

  16. Acute myeloid leukemia (AML) is an aggressive malignancy only cured by intensive therapy. However, many elderly and unfit patients cannot receive such treatment due to an unacceptable risk of treatment-related...

    Authors: Håkon Reikvam, Randi Hovland, Rakel Brendsdal Forthun, Sigrid Erdal, Bjørn Tore Gjertsen, Hanne Fredly and Øystein Bruserud
    Citation: BMC Cancer 2017 17:630
    Content type: Research article Published on: